Business Context and Reporting Period
This Form 6-K is filed by Midatech Pharma PLC (noted as Biodexa Pharmaceuticals Plc in request metadata) for the month of March 2019. The registrant is a foreign private issuer based in the United Kingdom, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a cover for a press release regarding a corporate action and does not contain financial statements or performance data.
Material Changes
The material change reported in this filing is a change to the American Depositary Receipt (ADR) ratio, as detailed in the attached press release dated March 20, 2019. No financial performance changes are disclosed in this specific text.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, or specific risk factors. The document is limited to the notification of the ADR ratio change.
Investor Verification Checklist
- Verify the specific details of the ADR ratio change in the attached press release (Exhibit 99.1).
- Confirm the impact of the ADR ratio change on the number of shares represented by each ADR.
- Check for any subsequent filings regarding the effective date of the ratio change.
- Note that this filing contains no financial performance data; refer to Form 20-F for financial metrics.